Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenfuqiangxin is a traditional Chinese medicine (TCM) patent drug formulated as oral pills or capsules. It is primarily used for the treatment of chronic heart failure (CHF), especially in patients with heart-kidney Yang deficiency syndrome—a TCM diagnostic category characterized by symptoms such as palpitations, breathlessness, chest tightness, puffy face, and swollen limbs. The formulation contains multiple herbal ingredients including Ginseng (Renshen), Radix aconiti carmichaeli (Fuzi), rhubarb (Dahuang), root bark of white mulberry (Sangbaipi), Polyporus umbellata, Semen lepidii (Tinglizi), and grifola (Zhuling). Mechanistically, preclinical studies suggest that Shenfuqiangxin exerts cardioprotective effects by modulating several signaling pathways involved in cardiac hypertrophy and apoptosis—such as inhibiting the mitogen-activated protein kinase pathway and regulating Bcl-2/Bax expression to reduce cardiomyocyte apoptosis. It also appears to improve water-sodium retention and protect renal function. Clinical trials have evaluated its efficacy and safety in CHF patients alongside standard Western therapies[5][1][6][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenfuqiangxin.